Richard J. Payne

Richard J. Payne


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2009 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
SASumeet M. Anand
Sumeet M. Anand
OGOlga Gologan
Olga Gologan
LRLouise Rochon
Louise Rochon
MTMichael Tamilia
Michael Tamilia
JHJacques How
Jacques How
RPRichard J. Payne
Richard J. Payne
The appropriate management of occult cervical lymph node metastasis in differentiated thyroid carcinoma (DTC) is controversial.1 Subclinical lymph node metastasis can be found in 27% to 90% of patients with DTC at the time of surgery or histologic examination.2-4 Although DTC has a high predilection to spread to regional lymph nodes, the prognostic significance of such regional metastasis is unclear. It has been shown that, in subsets of patients with DTC, particularly those younger than 45 years, lymph node metastasis is not associated with a decrease in survival.5,6 Other reports, on the contrary, state that lymph node metastasis is a significant prognostic factor that increases the risk of locoregional recurrence3,7,8 and survival.9,10 The presence of cervical lymph node metastasis can account for up to 75% of locoregional recurrence cases.11 In such instances, associated neck dissection improves the prognosis of patients with high-risk DTC.12

1 July 2014 in Urology
Verified
Journal Article
Closed access
MEMohamed A. Elkoushy
Mohamed A. Elkoushy
AYAlice X. Yu
Alice X. Yu
RTRoger Tabah
Roger Tabah
RPRichard J. Payne
Richard J. Payne
Alice DragomirAlice Dragomir
Alice Dragomir
SASero Andonian
Sero Andonian

1 July 2016 in Thyroid®
Verified
Journal Article
Closed access
MMMuhammad H. Mujammami
Muhammad H. Mujammami
MHMichael P. Hier
Michael P. Hier
RPRichard J. Payne
Richard J. Payne
LRLouise Rochon
Louise Rochon
MTMichael Tamilia
Michael Tamilia
Background: The study considered the long-term outcome of patients with papillary thyroid carcinoma treated with 30 mCi radioiodine. Objective: The aims of this study were to define and compare the remission rates of papillary thyroid carcinoma ablated with 30 mCi 131 I prepared by either thyroid hormone withdrawal (THW) or recombinant human thyrotropin (rhTSH; Thyrogen ® ), and to identify variables predictive of a favorable prognosis. Method: An observational study was conducted at an academic medical center and a comparative summary of six studies is presented. Three hundred and seventy patients (THW group, n = 203; rhTSH group, n = 167) were recruited from a prospectively managed registry. The mean follow-up was 9.3 years (range 5.1–15.8 years) in the THW group and 7.1 years (range 5.0–9.7 years) in the rhTSH group. The primary endpoint was the long-term remission rates (no evidence of disease) in the THW group compared with the rhTH group. Results: The response at 12–18 months after 30 mCi remnant ablation was excellent in 79.3% and 76.0% of patients in the THW group and the rhTSH group, respectively ( p > 0.05). The long-term remission rates also did not significantly differ between both groups at 95.6% and 97.0%. Although the surveillance period for the THW group exceeded that of the rhTSH group, no significant difference in recurrence-free survival was discerned by the Kaplan–Meier curves. In a multivariate analysis, an excellent response to therapy at 12–18 months correlated significantly with long-term remission rates in the THW group ( p = 0.031, odds ratio [OR] = 2.6 [confidence interval (CI) 1.1–6.0]), the rhTSH group ( p = 0.03, OR = 5.3 [CI 1.2–23.8]), and the pooled groups ( p = 0.001, OR = 3.43 [CI 1.63–7.2]). The pre-ablation thyroglobulin level significantly correlated with remission rates only in the THW group ( p = 0.035, OR = 5.5 [CI 1.1–27.1]). Conclusions: The response to remnant ablation with 30 mCi radioiodine is often excellent, and the long-term remission rates can be expected to be high, independent of the method of delivery (i.e., THW or rhTSH).

1 January 2018 in Journal of Otolaryngology - Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
DCDavid Chan
David Chan
KGK. Gong
K. Gong
MRM. G. Roskies
M. G. Roskies
VFV. I. Forest
V. I. Forest
MHMichael P. Hier
Michael P. Hier
RPRichard J. Payne
Richard J. Payne
Background: The American Thyroid Association published revised guidelines in 2015 on the management of differentiated thyroid cancer in adults. One of the key changes introduced in the revision proposes that diagnostic biopsy be based on ultrasound findings (i.e. size and nodule characteristics). The overall effect of these changes results in fewer nodules requiring biopsy. This study was conducted to determine if the changes to the guidelines will result in overlooked thyroid cancers, specifically malignancies with aggressive characteristics measuring between 1 and 1.49 cm. Methods: Patients ( n = 2083) with thyroid nodules who underwent total or subtotal/hemi thyroidectomy with or without neck dissection by a single surgeon between 2006 and 2016 were retrospectively enrolled. Demographic information and nodule characteristics were collected for all patients. Ultrasonography and final pathology reports were reviewed for patients with thyroid nodules between the sizes of 1–1.49 cm ( n = 155). Results: 45% ( n = 70) of patients with nodules between 1 and 1.49 cm were “low suspicion” nodules according to ultrasound. 47 of these nodules contained malignancies on final histopathological examination, 100% of which were of the papillary subtype. 21% ( n = 10) of these malignant nodules demonstrated extrathyroidal extension and 34% ( n = 16) were associated with regional metastases. Conclusions: Reliance on sonographic patterns alone could result in missed cancer diagnoses in patients with thyroid nodules measuring between 1 and 1.49 cm. Moreover, a portion of these malignancies may be associated with aggressive features. The effect of this finding on long-term outcomes is unclear.